A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
← catalyst calendarNCT06023589 · readout in 651 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Amgen.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
231estimated
Sites
147
Countries
Argentina, Brazil, Canada +19
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-24 | actual | When the study began enrolling |
| Primary completion | 2028-05-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-08-23 | estimated | The whole study's end, after follow-up |
| First posted | 2023-09-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Asthma
Interventions
- Biological: Tezepelumab — also filed as MEDI9929 and AMG157
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFAnnualized severe asthma exacerbation rate (AAER)
measured From Baseline to Week 52
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed